Blackstone raises $13 billion for Asia, double its previous fund

Blackstone Inc. has amassed $13.1 billion for an Asia private equity fund without leaning on its broader global platform, adding to a streak of massive pools raised by the industry’s giants in the region.

The buyout firm’s third Asia fund is more than twice the size of its 2021 pool on a standalone basis, surpassing its $10 billion target.

Overall, it’s about a fifth more than the previous vintage because the new fund didn’t receive commitments from the firm’s global buyout vehicle, according to Amit Dixit, Blackstone’s head of private equity for Asia. The 2021 pool included about $4.6 billion from the flagship fund.

“It’s the nature of the evolution in the Blackstone model,” Dixit said. Newer vehicles typically “start as a sharing with the global flagship fund, and as a programme matures and is successful, it becomes more standalone.”

The fundraising underscores a gap between global mega-managers and smaller rivals. Institutional investors, pinched by a broader slowdown in private equity distributions, are concentrating capital with firms that possess deep operating benches and a track record of boosting earnings, rather than relying on the multiple expansion that fuelled the region’s boom in the past decade.

The firm attracted 173 new investors, bringing the number of backers to 260, underscoring strong demand from first-time investors, he said. The capital raise comes as the New York-based firm doubles down on India and Japan, which have become central to its regional strategy and drivers of its strongest returns.

The push was bolstered by the performance of its second Asia fund, which has generated a net internal rate of return of 27% as of March, according to public filings.

Warburg Pincus Shuts Yuan Healthcare Fund on Deal Struggles

“The fundamental secret sauce is to be a builder of a business, not just a buyer of a business,” Dixit said. “If you build, you will get the strong performance, and if you get the strong performance, you will get investor interest.”

Some existing investors in the Asia programme increased their commitments by approximately 60% on average, while the investor base remained geographically diversified, with roughly 35% from North America, 25% from Asia, 20% from the Middle East and 15% from Europe, he said.

The firm will continue investing across Asia in technology, consumer, healthcare, financial services, and value-added industrials, while increasingly focusing on AI infrastructure and energy security as key emerging themes, Dixit said.

The firm has maintained a steady clip of exits, returning capital to backers via 15 sales over the past two years. Over the same period, Blackstone deployed more than $7 billion across 12 transactions in the region, according to the company.

Blackstone’s notable partial exits include Aster DM Healthcare Ltd. and International Gemological Institute Ltd., a certifier of lab-grown diamonds. Both transactions in India generated returns of about four times invested capital, people familiar said.

In Japan, the firm notched a win with Sony Payment Services Inc., a Tokyo-based payment processing carve-out that returned about 2.5 times invested capital, the people said.

The fundraising timeline reflects a tough market for private equity globally between 2024 and 2026. With limited partners constrained by slower distributions and overallocation concerns, marketing periods have lengthened for almost all but the largest managers.

Despite headwinds, the industry’s biggest names continue to raise capital. EQT AB closed its latest Asia buyout fund in April at $15.6 billion, marking the largest-ever pool of private equity assembled for the region. Bain Capital secured $10.5 billion for its sixth regional ex-Japan buyout fund in roughly six months, wrapping up one of the fastest fundraisings in Asia this year.

Blackstone in March also raised $6.2 billion for its latest life sciences fund, which finances late-stage clinical development of drugs and medical technologies.

Also Read: Wockhardt expects antibiotic Zaynich to become major growth driver after US launch